Home / Stocks / Onesource Specl Pharma L
ONESOURCE

Onesource Specl Pharma L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,602.9

Change

+16.7 (1.05%)

Open

₹1,587.0

Prev. Close

₹1,586.2

Day High

₹1,617.4

Day Low

₹1,570.0

Volume Analysis

Traded

126,006

Delivered

60,773

Delivery %

48.23%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (24.0%)

Weaknesses (2)

  • •Low return on equity (-1.09%)
  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year revenue growth (231.6%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,670.94 ₹1,644.17 ₹1,623.54 ₹1,596.77 ₹1,576.14 ₹1,549.37 ₹1,528.74
Fibonacci ₹1,644.17 ₹1,626.06 ₹1,614.88 ₹1,596.77 ₹1,578.66 ₹1,567.48 ₹1,549.37
Camarilla ₹1,615.94 ₹1,611.59 ₹1,607.25 ₹1,596.77 ₹1,598.56 ₹1,594.21 ₹1,589.87

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-10.34%

1 Week

-1.06%

1 Month

+18.11%

3 Months

+4.42%

6 Months

-12.62%

1 Year

-4.16%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-0.03%

Net margin -0.12% × asset turnover 0.17x × equity multiplier 1.45x

Company Overview

Sector

Healthcare

Market Cap

₹18,464 Cr

P/E (TTM)

1614.0

ROE

-1.09%

Book Value

₹516.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Onesource Specl Pharma L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (100/100), while Cash Flow (1/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (24.0%); low return on equity (-1.09%); promoter holding is falling. Strong 3-year revenue growth (231.6%).

TopFund Score — Fundamentals Quality

59/100 — Average

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

33

Cash Flow

1

Corporate Governance

27

Momentum

64

Institutional Ownership

83

Business Quality

39

Risk & Volatility

50

Liquidity

79

From Screener.in

  • −Stock is trading at 3.12 times its book value
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of -2.63% over last 3 years.
  • −Promoters have pledged 38.8% of their holding.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Company to participate in Jefferies Global Healthcare Conference in London, November 16-19, 2026.

Intimation of Transcript of Earnings call dated October 27, 2026

OneSource receives USFDA EIR with VAI for Bengaluru SPD facility after June 2026 inspection.

Intimation about publication of newspaper advertisement - Extract of unaudited Standalone and Consolidated financial results for the quarter and half year ended September 30, 2026.

Audio recording of Q2 FY27 earnings call held October 27, 2026, made available on website.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 34 56 73 292 334 393 426 327 376 290 428 449 516
Expenses + 72 67 76 228 257 251 243 239 269 273 336 326 353
Operating Profit -39 -10 -3 64 77 142 183 88 106 17 92 123 163
OPM % -114.0% -19.0% -3.8% 22.0% 23.0% 36.0% 43.0% 27.0% 28.0% 6.0% 21.0% 27.0% 32.0%
Other Income + -32 -74 3 -1 -1 -94 2 2 3 -2 2 0 -1
Interest 25 26 20 42 45 46 33 27 34 38 23 31 35
Depreciation 18 20 20 68 68 69 68 68 70 70 72 72 75
Profit before tax -114 -130 -40 -47 -37 -67 83 -4 6 -93 0 20 53
Tax % 0.0% 0.0% 0.0% -88.0% 12.0% 4.0% -19.0% -96.0% -83.0% -5.0% -1,630.0% -23.0% -9.0%
Net Profit + -114 -130 -40 -6 -42 -69 98 0 10 -89 5 25 57
EPS in Rs — — — — — -6 9 0 1 -8 0 2 5
Raw PDF — — — — — — — — — — — — —
YoY Sales growth — — — — 891 598 482 12 12 -26 1 37 37

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 21 132 39 172 1,445 1,422 1,684
Expenses + 93 229 199 254 978 1,117 1,288
Operating Profit -71 -97 -161 -82 467 304 396
OPM % -334.0% -73.0% -415.0% -48.0% 32.0% 21.0% 24.0%
Other Income + 1 4 -526 -143 -94 5 -2
Interest 16 68 48 89 166 122 126
Depreciation 34 70 66 76 274 279 288
Profit before tax -121 -231 -800 -391 -68 -92 -20
Tax % 0.0% 0.0% 0.0% 0.0% -73.0% -20.0% —
Net Profit + -121 -231 -800 -391 -18 -74 -2
EPS in Rs — — — — -2 -6 0
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 518 -71 344 740 -2 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 774 1,009 781 392 5,869 5,820 5,909
Borrowings + 386 1,154 864 562 772 1,276 1,755
Other Liabilities + 96 276 365 468 1,005 1,197 910
Total Liabilities 1,258 2,442 2,015 1,426 7,657 8,304 8,586
Fixed Assets + 633 1,231 1,361 863 6,118 6,017 6,445
CWIP 431 490 334 188 218 529 141
Investments 0 0 4 20 16 16 17
Other Assets + 195 722 314 356 1,305 1,742 1,983
Total Assets 1,258 2,442 2,015 1,426 7,657 8,304 8,586
Equity Capital 2 3 4 4 11 11 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -118 -416 -163 -107 -68 9
Cash from Investing Activity + -207 -692 -68 511 -201 -495
Cash from Financing Activity + 381 1,162 118 -391 412 359
Net Cash Flow 56 54 -112 13 143 -127
Free Cash Flow -325 -1,071 -207 -171 -196 -561
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 164 430 108 130 -13 6

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 37.76% → 30.47%
  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 32.24% 29.17% 33.42% 32.34% 32.01% 31.4% 26.95% 25.86%
Promoters 37.76% 34.25% 29.78% 29.77% 29.93% 30.48% 30.48% 30.47%
FII 17.44% 18.54% 18.69% 19.39% 19.24% 17.5% 19.19% 19.45%
DII 12.56% 18.03% 18.09% 18.48% 18.8% 20.61% 23.37% 24.2%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Onesource Specl Pharma L (this stock) 18,464 1614.0 3.12 -1.09%
Eris Lifesciences Limited 18,448 24.7 4.45 18.7%
Syngene International Ltd 17,935 67.5 3.7 7.78%
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%
Alivus Life Sciences Ltd 17,803 50.6 — —
Pfizer Ltd 17,601 115.0 12.74 19.8%
Shilpa Medicare Ltd 19,392 60.6 7.04 9.3%

Which Mutual Funds Hold Onesource Specl Pharma L?

Frequently Asked Questions about Onesource Specl Pharma L

Community Sentiment

What are other investors saying about Onesource Specl Pharma L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.